M3814
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for M3814, covering 2025-04-10 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy [Phase 1, Phase 2]